Here, our study reveals the previously unrecognized function of PIN1 in destabilizing pVHL and demonstrates the prospective clinical implication of directly targeting PIN1 by its inhibitor all-trans retinoic acid (ATRA) [28] in cancers with wild-type VHL including TNBC, other subtypes of breast cancers and pancreatic cancer, colorectal cancer, ovarian cancer and melanoma. This evidence concerns the gene PIN1 and ovarian cancer.